The corporate law firm Herbst Kinsky advised Marinomed Biotechnologie GmbH on the entry of INVEST Unternehmensbeteiligungs AG. After the participation of aws Mittelstandsfonds in Marinomed last fall Marinomed now convinced INVEST AG – another renowned investor – of its internationalization strategy.

Marinomed Biotechnologie GmbH was founded in 2006 as a spin-off from the Veterinary University of Vienna. Marinomed is specialised in the development of immunological and anti-viral treatments. The company has developed MAVIREX, a technology platform that targets virus strains based on Carragelose. In addition to other medicine products Marinomed research is currently also developing a medicine to treat autoimmune diseases.

INVEST AG with its headquarter in Linz is the investment arm of the Raiffeisen bank group of Upper Austria and is one of Austria’s leading private equity funds, with a fund volume of EUR 150 million. Since its founding in 1994, INVEST AG has already invested equity and mezzanine capital in more than 140 companies in a wide variety of sectors.

The team of Herbst Kinsky was led by Philipp Kinsky supported by Johannes Frank.